Ramucirumab + Capecitabine + Cisplatin + S-1 + Oxaliplatin
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stomach Neoplasms
Conditions
Stomach Neoplasms
Trial Timeline
Feb 1, 2015 → Nov 1, 2016
NCT ID
NCT02359058About Ramucirumab + Capecitabine + Cisplatin + S-1 + Oxaliplatin
Ramucirumab + Capecitabine + Cisplatin + S-1 + Oxaliplatin is a phase 1 stage product being developed by Eli Lilly for Stomach Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT02359058. Target conditions include Stomach Neoplasms.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02359058 | Phase 1 | Completed |
Competing Products
20 competing products in Stomach Neoplasms